In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

ESC Congress 2016 Hot Line tips

ESC Congress 2016 will be held 27 to 31 August in Rome, Italy



 

Sophia Antipolis, 16 August 2016: Get ready for the most highly anticipated cardiovascular science of the year in the ESC Congress 2016 hot lines. The primary results of 30 novel clinical trials will be presented, with findings revealed in advance to the media in six dedicated press conferences.

Be the first to hear the results of REVERSE II, a multi-national validation of a clinical decision rule to identify low risk unprovoked venous thromboembolism patients who can discontinue anticoagulants.

Find out whether direct or selective catheterisation guided by coronary computed tomography (CT) is the preferred choice in patients with stable suspected coronary artery disease from the findings of the randomised CONSERVE trial.

Also in the area of imaging, discover the outcome of the first head-to-head comparison of coronary CT angiography, myocardial perfusion SPECT, PET, and hybrid imaging for diagnosis of ischaemic heart disease in the PACIFIC trial. And get the answer to the question “Does Optical Coherence Tomography Optimise Results of Stenting?” in the randomised DOCTORS trial.

Exciting new science will be presented in the field of coronary stenting. ANTARCTIC will demonstrate whether platelet monitoring for dose adjustment of antiplatelet drugs is superior to a conventional fixed dose in elderly patients stented for an acute coronary syndrome. The results of a randomised comparison of ticagrelor and prasugrel in ST-segment elevation myocardial infarction will be unveiled in PRAGUE -18.

Don’t miss the randomised phase III trial results from ESCAPE on the effect of alirocumab on the frequency of lipoprotein apheresis, which removes low density lipoprotein (LDL) cholesterol from the blood.

Journalists will learn the latest prevention strategies in sleep apnoea (SAVE trial), and resistant hypertension, where outcomes with the novel median nerve modulation technique will be presented. Methods for cardiac rehabilitation have been compared in a randomised, controlled superiority trial of an educational and behavioral intervention and the results from OPTICARE will be released for the first time.

Innovative approaches for the treatment of heart failure will be divulged in DANISH, a randomised, controlled trial which examined the effect of an implantable cardioverter defibrillator on mortality in patients with non-ischaemic systolic heart failure.

This is just a small taste of the groundbreaking research that will be presented in this year’s hot lines. Additional late breaking science will presented in 25 clinical trial updates, 24 registries and 12 basic and translational hot lines presentations.

Four press conferences will be held on topics of interest to the press: the cardiovascular risks of modern life, stroke and arrhythmia, heart failure, and preventing sudden death with diet and devices

And available LIVE using this unique link

The press book will contain additional press releases on New ESC Guidelines on atrial fibrillation, dyslipidaemias, and cardio-oncology (position paper). Further insights will be given on the Joint European Cardiovascular Prevention Guidelines and the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, which were launched in May.

ENDS

 

Notes to editor

ESC Press Office
Tel: +33 (0)4 89 87 24 83 
Email: press@escardio.org / media@escardio.org

 

Journalists planning to attend are invited to register on-site from Friday 26 August midday, but may send their signed embargo form and press credentials now to press-registration@escardio.org to reduce waiting time in Rome.

  • Press credentials include a valid press identity card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related, or referring to a previous ESC Event).
  • The ESC media and embargo policy is here

 

* The press conference timetable is available here

 

* The press conference details is available here

 

* The press conference Livestream is available here


* Non Hot Line releases will be available under embargo on AlphaGalileo and EurekAlert a few days before ESC Congress. Hot Line releases will only be available when the embargo is lifted, online and on-site

 

* ESC Congress 2016 will take place from 27 to 31 August at the Fiera di Roma in Rome, Italy

* Information on Hot Line sessions is available here

 

* The scientific programme is available here.

 

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

 

About ESC Congress 2016

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org